• Graham Corporation recently reported first-quarter fiscal 2027 results showing sales rising to US$71.34 million from US$55.49 million a year earlier, while net income eased to US$3.91 million and diluted EPS from continuing operations slipped to US$0.33.
• Award of over US$43 million in new and follow-on defense contracts for submarine and torpedo programs, alongside reaffirmed full-year fiscal 2027 sales guidance of US$285 million to US$295 million, underscores how defense work is becoming an increasingly important driver within Graham’s backlog.
• We’ll now examine how strong defense contract wins, layered onto reaffirmed full-year guidance, may influence Graham’s existing investment narrative and assumptions.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Graham Investment Narrative Recap

To own Graham, you need to believe that record backlog and a growing defense footprint can translate into steadier revenue, even as margins fluctuate. The latest quarter reinforces that tension: sales grew, but earnings softened, and the key near term catalyst now rests on how efficiently Graham converts its heavier defense backlog into profit. The biggest current risk remains Graham’s dependence on a few large, long cycle Navy programs, where any slowdown or delay could abruptly change the story.

The reaffirmed full year fiscal 2027 sales guidance of US$285 million to US$295 million is the announcement that ties most directly to this update. It signals that management views the US$43 million in new submarine and torpedo awards as supporting the existing outlook rather than resetting it. For investors focused on backlog conversion and contract execution as near term catalysts, unchanged guidance after these wins invites closer scrutiny of how much incremental earnings power this defense work can really add.

Yet beneath the record backlog and reaffirmed guidance, investors should be aware of how exposed Graham still is if Navy procurement priorities shift or...

Graham's narrative projects $352.3 million revenue and $31.6 million earnings by 2029. This requires 12.8% yearly revenue growth and a $19.1 million earnings increase from $12.5 million today.

Uncover how Graham's forecasts yield a $125.75 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Compared with the consensus story, the most cautious analysts were already assuming about US$363.5 million of revenue and US$33.9 million of earnings by 2029, and they worry that Graham’s heavy tilt toward long cycle Navy torpedo and submarine work could backfire if defense budgets or platform choices move against these programs, so this quarter’s new awards and reaffirmed outlook may ultimately push their narrative in either direction once they reassess the numbers.

Explore 3 other fair value estimates on Graham - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Graham research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Graham research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Graham's overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.